We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cholesterol Metabolism and Lipid Transfer in Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01010035
Recruitment Status : Completed
First Posted : November 9, 2009
Last Update Posted : November 9, 2009
Information provided by:

November 6, 2009
November 9, 2009
November 9, 2009
September 2006
January 2009   (Final data collection date for primary outcome measure)
to identify the removal of the free and esterified cholesterol in type 2 diabetes patients [ Time Frame: day of test ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Cholesterol Metabolism and Lipid Transfer in Diabetes
Plasma Kinetics Study of Free Cholesterol and Cholesteryl Ester in Type 2 Diabetes Mellitus Patients
The diabetic dyslipidemia is one of the most important risk factor in the development of coronary artery disease. The low density lipoprotein (LDL)-like nanoemulsions is being used to study the clearance of cholesteryl ester and free cholesterol from intravascular in patients with advanced coronary artery disease and it was shown a higher removal of free cholesterol and higher deposit in vases of this patients. The aim of this study is to analyze the plasma kinetics of both forms of cholesterol(free ad esterified) in type 2 diabetes patients without a previous history of cardiovascular disease.
Hypercholesterolemia is not typical of type 2 diabetes mellitus dyslipidemia, but alterations in LDL may occur related to atherogenesis.Cholesterol exist in two main forms in organism: free cholesterol and the esterified cholesterol. An artificial model to study this two forms of cholesterol is the use of LDL-like nanoemulsion doubly labeled with 14C-cholesteryl esters and 3H- cholesterol. This nanoemulsion is made without protein and when in the intravascular compartment it is able to acquires apolipoproteins from others lipoproteins, such apos A's, C's and E. This model allowed us to use the nanoemulsion particle as a probe to study the lipoproteins receptor binding and the cholesterol esterification process.
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
whole blood samples
Non-Probability Sample
outpatient of the endocrinology clinics of Hospital das clinicas of University of São Paulo Medical school
Type 2 Diabetes Mellitus
Other: Plasma kinetic study
this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
Other Name: LDL-like nanoemulsion
  • type 2 diabetes
    patients with diagnosis of Type 2 diabetes mellitus
    Intervention: Other: Plasma kinetic study
  • Control
    non type 2 diabetes mellitus
    Intervention: Other: Plasma kinetic study

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2009
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • without a previous cardiovascular disease
  • if arterial hypertension, or in use of antihypertensive drugs- it must be well controled with a systolic Blood pressure level <130mmHg and diastolic <85mmHg.
  • total cholesterol < 6 mmol/L
  • LDL- cholesterol <4 mmol/L

Exclusion Criteria:

  • use of drugs- statins, fibrates, glucocorticoids, thiazolidinediones
  • nephropathy- the presence of microalbuminuria(ratio of microalbuminuria/creatinin >30 ug/mg) or serum creatinin above 98umol/L in woman and above 115 umol/L in man
  • retinopathy
  • neuropathy presence of chronic disease: heart failure, chronic obstructive pulmonary disease, inflammatory disease and cancer
Sexes Eligible for Study: All
40 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Antonio Carlos Lerario/ MD, PhD, university of são Paulo
University of Sao Paulo General Hospital
Fundação de Amparo à Pesquisa do Estado de São Paulo
Principal Investigator: Antonio C Lerario, MD, pHd University of São Paulo
University of Sao Paulo General Hospital
November 2009